

Market Announcement

23 February 2026

Rhythm Biosciences Limited (ASX: RHY) – Trading Halt

Trading in the securities of Rhythm Biosciences Limited ('RHY') will be halted at the request of RHY, pending the release of an announcement by RHY.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Wednesday, 25 February 2026; or
- the release of the announcement to the market.

RHY's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

23 February 2026

Melissa Kostopoulos
Listing Compliance Advisor, Listings Compliance
ASX Compliance Pty Ltd
525 Collins Street
North Tower Level 4
MELBOURNE VIC 3000

By email

Dear Melissa

Rhythm Biosciences Limited (ASX: RHY)

Request For Trading Halt

In accordance with ASX Listing Rule 17.1, Rhythm Biosciences Limited (ASX: **RHY**) (the **Company**) requests that its securities be placed into an immediate trading halt pending the release of an announcement in relation to a proposed underwriting agreement in relation to the Company's outstanding RHYO options.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Wednesday, 25 February 2026, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.

Please contact me if you require any further information.

Yours sincerely

Mark Licciardo
Company Secretary

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

E investors@rhythmbio.com

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

For personal use only